Navigation Links
Reportlinker Adds World Anti-Obesity Drug Market 2011-2021
Date:4/5/2011

NEW YORK, April 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Anti-Obesity Drug Market 2011-2021

http://www.reportlinker.com/p0470102/World-Anti-Obesity-Drug-Market-2011-2021.html

That will this decade hold for the challenged anti-obesity drug industry and market? Our new report gives you revenue forecasts at world, product and national level. 

We provide original research, data and opinions to benefit your work. By ordering now, you can stay ahead. We aim to save you time and benefit your decisions. 

How will the regulatory and marketing difficulties facing anti-obesity drugs affect companies and their revenues? In our report you will see prospects for obesity drug research, development, launches and marketing from 2011 onwards. 

We predict the overall world market and leading national markets. The increasing prevalence of obesity has created pharma market opportunities in many countries. 

Where will the best revenue prospects in obesity treatment lie from 2011 to 2021? Our study provides the answers you need for that pharma market.

Although sales have been modest so far, weight-loss drugs can gain acceptance from more prescribers, patients and payers. The prescription drug market for obesity can grow, despite setbacks at present, our study shows. You will see how. 

Anti-obesity drugs with improved clinical effectiveness, safety and ease of use can gain therapeutic and commercial success, our report explains. We show R&D progress there.

You will see strengths, weaknesses and revenue prospects of the anti-obesity drug market from 2009
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Reportlinker Adds World Biological Drugs Market 2011-2021
2. Reportlinker Adds World Influenza Vaccines Market 2011-2021
3. Reportlinker Adds Drug Delivery in Cancer - technologies, markets and companies
4. Reportlinker Adds Enzymes in Drug Manufacturing
5. Reportlinker Adds Personalized Medicine - Scientific & Commercial Aspects
6. Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies
7. Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing
8. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
9. Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
10. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
11. Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 National Community Pharmacists Association (NCPA) ... the following statement in response to a new ... documenting that a number of generic drug costs increased ... with concerns previously expressed by NCPA and underscores the ... to essential medications. Moreover, a 2015 survey of 700 ...
(Date:5/28/2015)... , May 27, 2015 The amount ... billion in 2014 and with growth of 8% will ... categories out of pocket: directly on expenditures, co-pays as ... purchases, and on premiums.  The publisher made its finding ... in the United States . ...
(Date:5/28/2015)...  The U.S. Department of Justice (DOJ) has entered ... Medical Inc. to resolve a lawsuit that began more ... whistleblower lawsuit by two former employees of Orbit.  The ... of one of Orbit,s top executives, Jake Kilgore ... payment from Medicare for electric wheelchairs.  The lawsuit was ...
Breaking Medicine Technology:NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4
... and FOSTER CITY, Calif., Dec. 11 /PRNewswire-FirstCall/,-- ... and Gilead Sciences, Inc.,(Nasdaq: GILD ) ... 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300,mg) ... suppressed adults with,HIV-1 infection, subject to the ...
... Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent ... ... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) announced today ... CPOP-R to CHOP-R in the,first-line treatment of patients with ...
Cached Medicine Technology:Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
(Date:5/28/2015)... 28, 2015 The Clinical Data ... that the International Organization for Standardization (ISO) now ... (BRIDG) Model version 3.2 as a published, Final ... with healthcare. This standard, which had previously passed ... was unanimously approved on 24 April for publication ...
(Date:5/28/2015)... 28, 2015 Park Cities Pet Sitter is ... Training class starting Saturday, June 6th at 10:30am. ... 5831 McCommas Blvd in Dallas, with a maximum of six ... for five weeks, with no class being held over the ... $135. , In this Intermediate-to-Advanced level class, dogs will solidify ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... opening a new location for his Shore Vascular & Vein ... treatment of the circulatory system. It is his mission ... compassion, consideration and respect. , Dr. Jeffrey Gosin ... a graduate of the University of Pennsylvania and Jefferson Medical ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... 2015 Medelis, Inc., a specialty oncology ... company in the role of president. , “ Bill Taaffe ... CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He ... our next phase of growth.” , Taaffe joined ICON’s ... nine employees to over 4,500 employees, achieving 12 consecutive years ...
Breaking Medicine News(10 mins):Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... plays a major role in kidney failure, and blocking the ... disease in diabetes, according to researchers. "We believe these ... can slow down the progression of, or even prevent the ... professor of nephrology, Penn State College of Medicine. In the ...
... News) -- Low vitamin D levels are common among spine ... says. Vitamin D helps with calcium absorption. Spine surgery ... producing new bone, explained researchers at Washington University School of ... spinal fusion surgery and found that more than half of ...
... , FRIDAY, Nov. 4 (HealthDay News) -- "Leatherhead" football ... modern helmets, a new study reports, but no one is ... researchers said their findings point to the need for improvements ... research team conducted lab tests to compare head injury risks ...
... crystallography, researchers Xiaohu Mei, PhD, and David Atkinson, PhD, from ... time obtained an "image" of the structure and the precise ... apolipoprotein A-I (apoA-I) molecule. The findings, which appear in the ... may lead to the development of new drugs to treat ...
... a new study being published early online in Annals ... College of Physicians, birth cohort screening for hepatitis C is ... strategy could identify over 800,000 currently unidentified cases, which could ... percent of the nation,s population is infected with hepatitis C ...
... A gene variation associated with an increased risk of autism ... three to four times more likely than girls to be ... genomic data from more than 3,000 children with autism and ... The results showed a link between a variation in the ...
Cached Medicine News:Health News:Research aims to prevent diabetic kidney failure 2Health News:Vitamin D Lacking in Many Spine Surgery Patients 2Health News:Newer Not Necessarily Better for Football Helmet Design 2Health News:Researchers identify structure of apolipoprotein 2Health News:Birth cohort screening for hepatitis C is cost effective, could save thousands of lives each year 2Health News:Possible Genetic Link to Autism Identified 2
An economical solution to the need to provide wrap-around protection. The one-sided velcro closure allows greater flexibility in sizing. Front protection is 0.5mm Pb and the back is 0.25mm Pb equival...
This wrap around apron features a uniquely designed orthopedic wide belt that is integrated directly on the apron....
The most comfortable and easy to use apron in the industry. This front protection apron comes with a fully adjustable snap-on 5" orthopedic belt to relieve weight off your shoulders. Velcro strap acr...
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Medicine Products: